AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

In 2020, life expectancy for people with cystic fibrosis was just 36. A new drug available on the NHS may be about to change ...

Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) severely affects patients’ quality of life and daily ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have ...

From birth jockey Harry Coffey has battled cystic fibrosis, a disease that wreaks havoc on the lungs. On Saturday he not only ...

"The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and ...